The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Rare Neurological Disease Treatment Global Market Report 2023, the rare neurological disease treatment market is expected to show significant growth in the forecast period.

Key insights from the rare neurological disease treatment market forecast include:

1. Market Size

The global rare neurological disease treatment market is expected to grow from $8.23 billion in 2022 to $8.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The rare neurological disease treatment market is expected to reach $12.36 billion in 2027 at a CAGR of 8.3%.

2. Major Driver

The prevalence of rare neurological diseases is expected to propel the growth of the rare neurological disease treatment market going forward. Rare neurological diseases refer to low-prevalence neurological disorders, including Huntington’s disease, ALS (amyotrophic lateral sclerosis), Rett syndrome, and various forms of muscular dystrophyFor instance, in January 2023, according to an article published by BioMed Central Ltd., a UK-based publisher of open-access scientific journals, the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a combined sample size of 9.57 million women, with a total of 673 confirmed cases. Additionally, in June 2020, according to The American Journal of Managed Care, a US-based publication specializing in managed care and healthcare delivery, the combined worldwide prevalence of individuals diagnosed with Duchenne muscular dystrophy (DMD) was determined to be 7.1 cases per 100,000 males. Therefore, the prevalence of rare neurological diseases is driving the growth of the rare neurological disease treatment market.

View More On The Rare Neurological Disease Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

3. Key Trend

The development of orphan pharmaceuticals is a key trend gaining popularity in the rare neurological disease treatment market. Major companies operating in the rare neurological disease treatment sector are focused on developing innovative and specialized treatments to strengthen their position in the market. For instance, in April 2023, Orphalan SA, a French orphan drug development company, introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is now commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and have shown tolerance to D-penicillamine. The drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.

4. Largest Region

North America was the largest region in the rare neurological diseases treatment market in 2022.

5. Major Players

Major players in the rare neurological disease treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., and Retrotope Inc.

Request A Sample Of The Global Rare Neurological Disease Treatment Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12146&type=smp

Key Rare Neurological Disease Treatment Market Segments
The global rare neurological disease treatment market is segmented –
1) By Drug Type: Biologics, Small Molecules
2) By Therapy: Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies
3) By Mode Of Administration: Oral, Injectable, Other Modes Of Administration
4) By Disorders: Aicardi Syndrome, Aicardi-Goutières Syndrome, Reflex Sympathetic Dystrophy Syndrome, Battaglia-Neri Syndrome, Creutzfeldt Jakob Disease, Agnosia, Other Disorders
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Store, Online Pharmacies

The Rare Neurological Disease Treatment Global Market Report 2023  provides an in-depth analysis on the rare neurological disease treatment market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the rare neurological disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Rare Diseases Treatment Global Market Report 2023
Neurology Devices Global Market Report 2023
Interventional Neurology Devices And Equipment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model